Conference call/webinar on bipolar androgen therapy (BAT)

For those who are interested, the Answer Cancer Foundation has let us know that they will be holding an educational conference call/webinar at 8:00 pm Eastern (5:00 pm Pacific) today on the subject of bipolar androgen therapy in the treatment of advanced prostate cancer. … READ MORE …

Aggressive, neoadjuvant androgen ablation prior to surgery in higher risk prostate cancer patients

The development of drugs like abiraterone acetate and enzalutamide has stimulated new research into the use of such agents early on, in combination with first-line therapy, to see if it can affect the outcomes for men with high-risk and unfavorable intermediate-risk prostate cancer. … READ MORE …

Real care beyond medical treatment, and impact on quality of life

A small, recent pilot study in Geneva, Switzerland, has shown that radiation therapy (RT) + androgen deprivation therapy (ADT) can be given safely to frail patients with non-metastatic, locally advanced or aggressive, intermediate prostate cancer, if and when a multidisciplinary care program is implemented to help such frail patients to limit risk for and manage predictable side effects. … READ MORE …

ADT + EDT in the treatment of advanced prostate cancer?

An article published on line last year in Anticancer Research has just come to our attention. It puts forward the relatively simple proposal that by combining androgen deprivation therapy (ADT) with estrogen deprivation therapy (EDT) we might be able to significantly impact the risk for development of castration-resistant prostate cancer (CRPC). … READ MORE …

IADT — pro and con; a follow-up

The other day we mentioned two articles in a recent issue of JAMA Oncology that dealt with the role of intermittent androgen deprivation therapy (IADT) in the management of progressive prostate cancer today. We have now had the good fortune to be able to read both of the two articles in full, thanks to a kind correspondent. … READ MORE …

Starting the new year with two of the usual controversies

Strictly speaking, JAMA Oncology actually ended the old year (in its issue on December 29, 2016), rather than beginning the new one, with two articles, a letter to the editor, and an editorial that deal with two of the more controversial issues that affect the way we think about the management of prostate cancer. … READ MORE …

Serious pneumonia: yet another potential complication of treatment with ADT

It has been known for some time that androgen deprivation therapy (ADT) may increase risk for pneumonia because, normally, androgen levels have effects on how well the immune system works and on the health of lung tissue. … READ MORE …